Titlebook: Advances in Research on Neurodegeneration; Volume 6 W. Poewe,G. Ransmayr Conference proceedings 1999 Springer-Verlag Wien 1999 Huntington‘s

交叉路口

书目名称Advances in Research on Neurodegeneration影响因子(影响力)




书目名称Advances in Research on Neurodegeneration影响因子(影响力)学科排名




书目名称Advances in Research on Neurodegeneration网络公开度




书目名称Advances in Research on Neurodegeneration网络公开度学科排名




书目名称Advances in Research on Neurodegeneration被引频次




书目名称Advances in Research on Neurodegeneration被引频次学科排名




书目名称Advances in Research on Neurodegeneration年度引用




书目名称Advances in Research on Neurodegeneration年度引用学科排名




书目名称Advances in Research on Neurodegeneration读者反馈




书目名称Advances in Research on Neurodegeneration读者反馈学科排名

GULP

艰苦地移动

,Molecular mimicry and multiple sclerosis — a possible role for degenerate T cell recognition in theort the hypothesis that the pathogenesis is mediated by autoreactive T lymphocytes. Molecular mimicry has been proposed as a possible mechanism for the development of an autoimmune response to myelin antigens. According to this model, an immune reaction to self antigens could be initiated by T cells

水獭

安抚

自爱

多嘴

enumaerate

,Antiglutamate therapy of ALS — which is the next step?, in men indicates that antiglutamatergic strategies are the first to have an influence on its pathogenesis and slow down the disease process. Since the effect of the drugs is still small, this progress cannot only be seen as a success of the present but most also be acknowledged as a starting point

ACTIN

,Antiglutamate therapies in Huntington’s disease,netic defect leads to neuronal injury and death is unknown, but is thought to include glutamate-mediated excitotoxicity and abnormalities of mitochondrial energy production. Both of these mechanisms may lead to a final common pathway of increased production of free radical species. Prior clinical tr

显示

Neural transplantation in animal models of multiple system atrophy: a review,Due to combined degeneration of substantia nigra pars compacta (SNC) and of striatum, antiparkinsonian therapy based on levodopa substitution eventually fails in more than 90% of patients. Animal models of MSA-SND are urgently required as test-bed for the evaluation of novel therapeutic intervention